Compare Travere Therapeutics Inc. Common Stock (TVTX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs United Microelectronics Corp — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while United Microelectronics Corp trades at $20.78 (market cap $55.52B). The key difference: United Microelectronics Corp is far larger — about 11.4× Travere Therapeutics Inc. Common Stock's market cap, and United Microelectronics Corp pays a 1.79% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and United Microelectronics Corp for 42 Days on average.
| TVTX | UMC | |
|---|---|---|
Market Cap | $4.88B | $55.52B |
Volume | 1,668,577 | 8,712,351 |
Sector | Health | Technology |
52-Week High | $67.52 | $28.02 |
52-Week Low | $26.79 | $7.02 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $5.01B | $52.61B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
UMC trades at $21.40, down 5.1% in the past 24 hours, with mixed technical signals showing a bearish moving average trend but oversold RSI conditions. Fundamentally, the company demonstrates strong profitability with 32.75% net income margin and has beaten earnings estimates for three consecutive quarters, though revenue growth remains modest at 2.3% year-over-year for 2025.
The stock presents a mixed outlook with strong earnings performance and attractive valuation metrics offset by slowing revenue growth and competitive pressures. Analyst sentiment leans cautious with a 'Hold' consensus, while technical indicators suggest potential near-term support around current levels given oversold conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
